Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol

New England Journal of Medicine

Volumn 341, Issue 6, 1999, Pages 410-418

  Rubins, Hanna Bloomfield ^h   Robins, Sander J ^a   Collins, Dorothea ^a   Fye, Carol L ^b   Anderson, James W ^c   Elam, Marshall B ^d   Faas, Fred H ^e   Linares, Esteban ^f   Schaefer, Ernst J ^a   Schectman, Gordon ^a   Wilt, Timothy J ^a   Wittes, Janet ^g  

^a Dept Vet Aff Coop Studs P ^*

^b University of New Mexico   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^f VA MEDICAL CENTER   (Puerto Rico)

^g University of Iowa   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOPID SR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIARY TRACT DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DYSPEPSIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GEMFIBROZIL; HUMANS; HYPOLIPOPROTEINEMIAS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RISK; TRIGLYCERIDES;

EID: 0033527030     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908053410604     Document Type: Article

References (37)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
4. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75:1196-201.
5. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67:1185-9.
6. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
7. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-6.
8. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13.
9. Rubins HB, Robins SJ, Iwane MK, et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993;71:45-52.
10. Iwane MK, Wittes J, Collins DE, Rubins HB. Simultaneous screening for three correlated lipids in the VA HDL Intervention Trial. J Clin Epidemiol 1999;52:685-93.
11. Schaefer EJ, Lamon-Fava S, Cole T, et al. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoprotcins in hypercholesterolemic patients with decreased HDL cholesterol levels. Atherosclerosis 1996;127:113-22.
12. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston: John Wright/PSG, 1982.
14. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials 1986;7:189-99.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;3:163-70.
16. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34 187-202.
17. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics 1988;44:579-85.
18. Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996;78:572-5.
19. Miller DB. Secondary prevention for ischemic heart disease: relative numbers needed to treat with different therapies. Arch Intern Med 1997; 157:2045-52.
20. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation 1992;85:1960-8.
21. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
22. Hill SA, McQueen MJ. Reverse cholesterol transport - a review of the process and its clinical implications. Clin Biochem 1997;30:517-25.
23. Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993;294:829-34.
24. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
25. Ginsberg HN. Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Med 1997;126:912-4.
26. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-6.
27. Lamarche B, Tchernof A, Mauriege P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955-61.
28. Yuan J, Tsai MY, Hunninghake DB. Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1-11.
29. Weintraub MS, Eisenberg S, Breslow JL. Different patterns of post-prandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals: effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987;79:1110-9.
30. Bhatnagar D, Durrington PN, Mackness MI, Arrol S, Winocour PH, Prais H. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis 1992;92:49-57.
31. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;79:1615-22.
32. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J 1978;40:1069-118.
33. Huttunen JK, Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 1994;235: 31-9.
34. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
35. Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446-52.
36. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97: 1453-60.
37. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97:1436-9.